XRAY DENTSPLY SIRONA Inc.

INVESTOR ALERT: Investigation of Dentsply Sirona Announced by Holzer & Holzer

Holzer & Holzer, LLC is investigating whether Dentsply Sirona, Inc. (“Dentsply” or the “Company”) (NASDAQ: XRAY) complied with the federal securities laws. On September 29, 2017, Dentsply reported more than a billion dollar loss for its second quarter, which was followed by the resignation of its top executive officers. Dentsply also has disclosed that it is cooperating with a Securities and Exchange Commission investigation into its accounting practices.

If you purchased Dentsply common stock and suffered a loss on that investment, you are encouraged to contact Corey D. Holzer Esq. at [email protected] or Marshall P. Dees, Esq. at [email protected], or call the firm by toll-free telephone at (888) 508-6832.

Holzer & Holzer, LLC is an Atlanta, Georgia law firm that dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. More information about the firm is available through its website, www.holzerlaw.com and upon request from the firm. Holzer & Holzer, LLC has paid for the dissemination of this promotional communication, and Corey D. Holzer is the attorney responsible for its content.

EN
04/10/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on DENTSPLY SIRONA Inc.

Dentsply Sirona Inc.: Update to credit analysis

Our credit view of this issuer reflects its moderate financial leverage and its strong market position in the dental device industry, against its high reliance on distributors.

Dentsply Sirona Inc: 2 directors

Two Directors at Dentsply Sirona Inc bought 20,000 shares at between 12.445USD and 12.480USD. The significance rating of the trade was 70/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors ove...

 PRESS RELEASE

First-ever Dental Dedicated MRI Validated in Clinical Trial and Cleare...

First-ever Dental Dedicated MRI Validated in Clinical Trial and Cleared by FDA for Advanced Soft-Tissue Diagnostics Dentsply Sirona and Siemens Healthineers are pleased to announce that the first-ever dental-dedicated MRI1 (ddMRI) system – MAGNETOM Free.Max Dental Edition – has received FDA clearance in the United States. This milestone follows the completion of a clinical trial2 validating the system’s significant potential across multiple dental specialties. The trial highlighted this first-of-its-kind technology’s applicability in endodontics, periodontics, TMJ, tooth extraction, and ort...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: March 7, 2026

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

ResearchPool Subscriptions

Get the most out of your insights

Get in touch